Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Cardiovascular Endocrinology

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1667438

This article is part of the Research TopicCardiovascular Risks in Cardiovascular-Kidney-Metabolic Syndrome: Mechanisms and TherapiesView all 7 articles

Revealing the Hidden Impact of SGLT2 Inhibitors on Uric Acid Levels: A Retrospective Multicenter Cohort Study

Provisionally accepted
Ehsan  A HabeebEhsan A Habeeb1Abdullah  M GhaithAbdullah M Ghaith2Abdulmajeed  AlshehriAbdulmajeed Alshehri3*Ghalia  AquilGhalia Aquil4Arwa  H AfanaArwa H Afana4Ali  H AlqarafiAli H Alqarafi1Abdullah  A AlahmedAbdullah A Alahmed5, Omar  S Alkhezi, Omar S Alkhezi6
  • 1Taibah University, Medina, Saudi Arabia
  • 2Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
  • 3King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
  • 4King Faisal Specialist Hospital & Research Centre - Jeddah, Jeddah, Saudi Arabia
  • 5Qassim University, Qassim, Saudi Arabia, Qassim, Saudi Arabia
  • 6Qassim University, Buraydah, Saudi Arabia

The final, formatted version of the article will be published soon.

Abstract Introduction: Hyperuricemia, characterized by elevated serum uric acid (UA) levels, is associated with cardiovascular–kidney–metabolic syndrome and remains challenging to manage due to medication side effects and adherence issues. SGLT2 inhibitors (SGLT2i), primarily prescribed for diabetes (DM), heart failure (HF), and chronic kidney disease (CKD), have demonstrated potential UA-lowering effects, though their precise impact is not well established. Methods: This multicenter retrospective cohort study used a pre-and-post analysis to evaluate the effect of SGLT2i on UA levels. Data were collected from four major healthcare centers in Saudi Arabia. The study included adult patients who initiated SGLT2i therapy between January 2022 and January 2024, excluding those with active gout flares, a history of cancer, or recent changes in UA-lowering therapy. The primary outcome was the percentage change in serum UA levels post-i initiation, with secondary outcomes including subgroup analyses, metabolic effects, univariate and multivariate modeling, and longitudinal trend evaluations. Results: Among 2,400 patients screened, 454 were included in the final analysis. SGLT2i significantly reduced UA levels by 4.5% (p=0.006), with the most pronounced reduction in patients with baseline elevated UA (10%, p=0.001) and those with HF (9%, p=0.001). Univariate analysis identified DM & HF, DM & CKD, and DM, HF & CKD as predictors of response, but multivariate analysis confirmed only DM & HF as an independent predictor (OR = 2.2, 95% CI: 1.2–4.04). Conclusion: These findings suggest that SGLT2i may serve as an adjunct therapy for hyperuricemia, especially in patients with DM & HF, highlighting the need for further research on long-term benefits.

Keywords: Hyperuricemia, SGLT2 inhibitors, Uric Acid, diabetes, Heart Failure, Chronic Kidney Disease

Received: 16 Jul 2025; Accepted: 02 Oct 2025.

Copyright: © 2025 Habeeb, Ghaith, Alshehri, Aquil, Afana, Alqarafi, Alahmed and Alkhezi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Abdulmajeed Alshehri, abdulmajeed483@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.